Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

NICE requestes more information on Jardiance for Type 2 Diabetes- Boehringer

30-Aug-2014

In new draft guidance the National ...

Post marketing study of Actos shows no increased risk of Bladder Cancer in Diabetes patients-Takeda

30-Aug-2014

Takeda has announced the completion ...

Mylan files in FDA for generic Copaxone for Multiple Sclerosis.

30-Aug-2014

Mylan Inc. announced that its ...

Trials show Androxal superior in Secondary Hypogonadism-Repros Therapeutics

29-Aug-2014

Repros Therapeutics reported top line ...

Amgen files evolocumab at FDA for treatment of High Cholesterol

29-Aug-2014

Amgen has announced the submission ...

Evolocumab success in YUKAWA-1 trial for patients with High Cardiovascular Risk and High Cholesterol- Amgen

29-Aug-2014

Amgen has announced that the Phase ...

FDA approves Promacta for severe aplastic Anaemia-GSK

28-Aug-2014

The FDA has approved a supplemental ...

Recent Updates

Drugs

Clinical Guidelines

Diagnosis and management of colorectal cancer

Interdisciplinary European Guidelines on Surgery of Severe Obesity

Psychosis with coexisting substance misuse: Assessment and management in adults and young people

Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines

Medical Journals

Circulating ?/? T cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of proalpha2(I) collagen of fibroblasts

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Cannabis withdrawal in chronic cannabis users with schizophrenia

Silk protein hydrolysate increases glucose uptake through up-regulation of GLUT 4 and reduces the expression of leptin in 3T3-L1 fibroblast

epgonline.org Social